ClinicalTrials.gg
CompletedNCT00094835Updated Mar 24, 2016Results posted

Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

A Phase 1/2 interventional study of Panitumumab and Motesanib diphosphate in Lung Cancer and Non-Small Cell Lung Cancer, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-24.

Primary conditionCarcinoma, Non-Small-Cell LungRegistry: Lung NeoplasmsReclassifiedWhy we changed it
Registry
Lung Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Non-Small-Cell Lung
Why
  1. The study's listed conditions name Carcinoma, Non-Small-Cell Lung, a narrower term within Lung Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
51
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing panitumumab in Carcinoma, Non-Small-Cell Lung — none open to participants now, none under way, none of them phase 3. Panitumumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
5th of 10
51 · median 51
Started
2005
the only one that year
Phase 1/2
Only one
of the 11
Registered
3rd of 11
by date
Lead sponsor
5 of 11
Amgen

Among the 11 studies testing panitumumab in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2005, is the only one in phase 1/2, and was the 3rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

None of the 11 studies testing panitumumab in Carcinoma, Non-Small-Cell Lung is open now. The open studies under Carcinoma, Non-Small-Cell Lung, anywhere →

Where they have run

About panitumumab

Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing panitumumab in Carcinoma, Non-Small-Cell Lung as a file.
02

Study summary

The purpose of this trial is: - To characterize the safety profile of motesanib when used in combination with carboplatin/paclitaxel (CP), with panitumumab or with CP and panitumumab in patients with advanced non-small cell lung cancer (NSCLC). - To establish the pharmacokinetic (PK) profile of motesanib when it is used in combination with CP, with panitumumab, or with CP and panitumumab. - To compare the paclitaxel and motesanib PK profiles when the medications are administered 30 minutes (min) or approximately 48 hours (hrs) apart. - To characterize the panitumumab and paclitaxel exposure in the combination regimens of motesanib with CP, motesanib with panitumumab, or motesanib with CP and panitumumab. - To describe the objective response rate (ORR) in each dose cohort. - To measure the immunogenicity of panitumumab in patients administered motesanib with panitumumab and motesanib with CP and panitumumab.

Read the detailed description

This was a multicenter, open-label, dose-finding clinical trial examining the safety and PK of once or twice daily motesanib administered with CP or with CP and panitumumab in chemotherapy naïve patients, and with panitumumab in patients with no more than one prior chemotherapy regimen for NSCLC.

Participants were enrolled into the Panitumumab + Paclitaxel + Carboplatin + Motesanib once a safe and tolerable dose of AMG 706 was established in the other treatment arms.

03

Conditions studied

  • Lung Cancer
  • Non-Small Cell Lung Cancer

Browse trials for

Keywords

  • Lung cancer, Non-small cell lung cancer, NSCLC
  • Clinical Trial, Panitumumab, AMG 706
  • Anti-angiogenesis
  • Immunex, Abgenix, Amgen
  • Stage IIIB, Stage IV, Unresectable
04

In context

Carcinoma, Non-Small-Cell Lung Reclassified

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

This study's enrollment of 51 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of unresectable stage IIIB or IV non-small cell lung cancer (NSCLC)
  • No more than one prior chemotherapy
  • Adequate hematologic, renal and hepatic function
  • or evaluable disease on CAT scan or MRI
  • (ECOG) performance status of 0 or 1
  • Able to fast for 10 hrs twice during the study - Able to tolerate oral medications
  • of at least 3 months

Exclusion criteria

Exclusion Criteria:

  • Symptomatic or untreated central nervous system requiring current treatment
  • History of arterial thrombosis within 1 year prior to enrollment
  • Anticoagulant therapy, except for warfarin of less than 2mg per day
  • Symptomatic peripheral neuropathy
  • History of pulmonary hemorrhage or hemoptysis
  • Myocardial infarction within 1 year before enrollment
  • Uncontrolled hypertension [diastolic greater than 85 mmHg; systolic greater than 145 mmHg]
  • History of other cancer, unless treated with no known active disease for longer than 3 years
  • Previous treatment with AMG 706 or panitumumab, previous treatment with inhibitors of VEGF or EGF
  • No antibody treatment for 6 weeks prior to enrollment
  • Known positive, positive or surface antigen positive
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Paclitaxel + Carboplatin + Motesanib

    Chemotherapy naïve participants received paclitaxel 200 mg/m\^2 and carboplatin chemotherapy administered by intravenous (IV) infusion on Day 1 of each 21-day cycle, and motesanib, orally self-administered on Days 3-21 of Cycle 1 and then on Days 1 to 21 of Cycle 2 and all cycles thereafter. The initial dose of motesanib was 50 mg once daily administered in the initial cohort and up to 125 mg once daily was used in subsequent cohorts. A cycle was defined as the 3 weeks plus the time to recover from toxicity, if encountered.

    Drug: Motesanib diphosphate · Drug: Paclitaxel · Drug: Carboplatin

  • Experimental
    Panitumumab + Motesanib

    Participants with no more than one prior chemotherapy regimen for NSCLC received panitumumab administered by IV at 9.0 mg/kg on Day 1 of each 21-day cycle, and motesanib, orally self-administered on Days 3-21 of Cycle 1 and then on Days 1 to 21 of Cycle 2 and all cycles thereafter. The initial dose of motesanib was 50 mg once daily administered in the initial cohort, up to 125 mg once daily was used in subsequent cohorts.

    Biological: Panitumumab · Drug: Motesanib diphosphate

  • Experimental
    Panitumumab + Paclitaxel + Carboplatin + Motesanib

    Chemotherapy naïve participants received panitumumab administered by IV at 9.0 mg/kg on Day 1 of each 21-day cycle, paclitaxel 200 mg/m\^2 and carboplatin chemotherapy administered by IV infusion on Day 1 of each 21-day cycle, and motesanib, orally self-administered on Days 3-21 of Cycle 1 and then on Days 1 to 21 of Cycle 2 and all cycles thereafter. Participants were enrolled in this arm once a safe and tolerable dose of motesanib was established.

    Biological: Panitumumab · Drug: Motesanib diphosphate · Drug: Paclitaxel · Drug: Carboplatin

Interventions

  • BiologicalPanitumumab

    9.0 mg/kg on Day 1 of each 21-day cycle administered by intravenous infusion over approximately 60 minutes.

    Also known as: Vectibix, ABX-EGF

  • Dose-finding with an initial dose of 50 mg once daily and up to 125 mg once daily. 75 mg twice daily was also to be tested.

    Also known as: AMG 706

  • Paclitaxel 200 mg/m\^2 administered by IV infusion over 3 hours.

  • Carboplatin was administered IV over approximately 30 minutes. Carboplatin was dosed using the glomerular filtration rate (GFR) and Calvert formula to AUC/time curve of 6 mg/mL×min.

07

What researchers measure

Primary outcomes

  1. Time to Maximum Plasma Concentration of Motesanib (Tmax) for Cycle 1

    The time after dosing that the maximal plasma concentration of motesanib was observed in Cycle 1. For the 75 mg BID cohorts, Tmax is reported for the first daily dose.

    Time frame: Cycle 1, Day 3 at predose, 15 and 30 minutes, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.

  2. Maximum Observed Plasma Concentration of Motesanib (Cmax) in Cycle 1

    The maximal observed plasma concentration of motesanib after a single dose dose in Cycle 1. For the 75 mg BID cohorts, Cmax is reported for the first daily dose.

    Time frame: Cycle 1, Day 3 at predose, 15 and 30 min, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.

  3. Estimated Terminal-phase Half-life (t1/2,z) of Motesanib in Cycle 1

    The terminal-phase elimination half-life (t1/2,z) of motesanib was calculated as ln(2)/λz. The terminal elimination rate constant (λz) was determined by linear regression of the natural logarithms of at least the last 3 measurable concentrations during the terminal phase. For the 75 mg BID cohorts, t1/2,z is reported for the first daily dose.

    Time frame: Cycle 1, Day 3 at predose, 15 and 30 min, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours postdose.

  4. Area Under the Plasma Concentration-time Curve for Motesanib in Cycle 1

    Area under the plasma concentration-time curve for motesanib in Cycle 1 calculated using the using the linear/log trapezoidal method. AUC from time zero to infinity (AUC0-inf) is reported for the 50 and 125 mg QD cohorts and AUC from time 0 to 24 hours post-dose (AUC0-24) is reported for the 75 mg BID cohort, where AUC0-24 is the sum of AUC0-12 for the first and second daily dose.

    Time frame: Cycle 1, Day 3 at predose, 15 and 30 minutes, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.

  5. Trough Plasma Concentration at 24 Hours Post-dose (C24) for Motesanib in Cycle 1

    The trough plasma concentration for motesanib at 24 hours postdose in Cycle 1. For the 75 BID cohort, C24 is the observed concentration at 24 hours (ie, after the second daily dose).

    Time frame: Cycle 1, Day 3, 24 hours post-dose

  6. Time to Maximum Plasma Concentration of Motesanib (Tmax) in Cycle 2

    The time after dosing that the maximal plasma concentration of motesanib was observed in Cycle 2. For the 75 mg BID cohorts, Tmax is reported for the first daily dose.

    Time frame: Cycle 2, Day 1 at predose, 15 and 30 min, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.

  7. Maximum Observed Plasma Concentration of Motesanib (Cmax) in Cycle 2

    The maximal observed plasma concentration of motesanib in Cycle 2, after multiple doses. For the 75 mg BID cohorts, Cmax is reported for the first daily dose.

    Time frame: Cycle 2, Day 1 at predose, 15 and 30 min, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.

  8. Estimated Terminal-phase Half-life (t1/2,z) of Motesanib in Cycle 2

    The terminal-phase elimination half-life (t1/2,z) of motesanib was calculated as ln(2)/λz. The terminal elimination rate constant (λz) was determined by linear regression of the natural logarithms of at least the last 3 measurable concentrations during the terminal phase. For the 75 mg BID cohorts, t1/2,z is reported for the first daily dose.

    Time frame: Cycle 2, Day 1 at predose, 15 and 30 min, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.

  9. Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours Post-dose for Motesanib in Cycle 2

    Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC0-24) for motesanib in Cycle 2 calculated using the using the linear/log trapezoidal method. For the 75 mg BID cohort AUC0-24 is the sum of AUC0-12 for the first and second daily dose.

    Time frame: Cycle 2, Day 1 at predose, 15 and 30 minutes, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.

  10. Trough Plasma Concentration at 24 Hours Post-dose (C24) for Motesanib in Cycle 2

    The trough plasma concentration for motesanib at 24 hours postdose in Cycle 2. For the 75 BID cohort, C24 is the observed concentration at 24 hours (ie, after the second daily dose).

    Time frame: Cycle 2, Day 1, 24 hours post-dose

Secondary outcomes

  1. Percentage of Participants With an Overall Objective Response

    Confirmed objective tumor response defined as a complete response (CR) or partial response (PR) using modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. Tumor response was evaluated by computed tomography (CT) scan or magnetic resonance imaging (MRI). Responding disease (CR or PR) was confirmed no less than 4 weeks after the criteria for response were first met. A complete response defined as the disappearance of all target lesions and all non-target lesions, no new lesions and normalization of tumor marker level. Partial response defined as either the disappearance of all target lesions and the persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits, or, at least a 30% decrease in the sum of the longest diamer (LD) of target lesions, taking as reference the baseline sum LD and no new lesions and/or unequivocal progression of existing non-target lesions.

    Time frame: After 9 weeks of treatment (at the end of Cycle 3)

08

Results

Posted Mar 24, 2014

Participant flow

Participants were enrolled from 18 January 2005 through 25 September 2006

Participant flow — Overall Study
MilestonePaclitaxel/Carboplatin + Motesanib 50 mg QDPaclitaxel/Carboplatin + Motesanib 125 mg QDPaclitaxel/Carboplatin + Motesanib 75 mg BIDPanitumumab + Motesanib 50 mg QDPanitumumab + Motesanib 125 mg QDPanitumumab + Motesanib 75 mg BIDPanitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QD
Started91175766
Treated with motesanib61164756
Completed5844334
Not completed4331432
Withdrew: Physician decision1000010
Withdrew: Withdrawal by subject0000001
Withdrew: Lost to follow-up0000100
Withdrew: Death1000100
Withdrew: Non-compliance1220221
Withdrew: Other1111000

Outcome measures

PrimaryTime to Maximum Plasma Concentration of Motesanib (Tmax) for Cycle 1

The time after dosing that the maximal plasma concentration of motesanib was observed in Cycle 1. For the 75 mg BID cohorts, Tmax is reported for the first daily dose.

Time frame:
Cycle 1, Day 3 at predose, 15 and 30 minutes, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.
Reported as:
Median · hours
Time to Maximum Plasma Concentration of Motesanib (Tmax) for Cycle 1
hoursPaclitaxel/Carboplatin + Motesanib 50 mg QDPaclitaxel/Carboplatin + Motesanib 125 mg QDPaclitaxel/Carboplatin + Motesanib 75 mg BIDPanitumumab + Motesanib 50 mg QDPanitumumab + Motesanib 125 mg QDPanitumumab + Motesanib 75 mg BIDPanitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QD
Time to Maximum Plasma Concentration of Motesanib (Tmax) for Cycle 10.75 (0.5 to 2.0)1.0 (0.5 to 6.0)0.75 (0.25 to 1.00)1.5 (0.5 to 4.0)1.0 (0.5 to 1.0)0.58 (0.50 to 1.00)1.0 (1.0 to 4.0)
SecondaryPercentage of Participants With an Overall Objective Response

Confirmed objective tumor response defined as a complete response (CR) or partial response (PR) using modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. Tumor response was evaluated by computed tomography (CT) scan or magnetic resonance imaging (MRI). Responding disease (CR or PR) was confirmed no less than 4 weeks after the criteria for response were first met. A complete response defined as the disappearance of all target lesions and all non-target lesions, no new lesions and normalization of tumor marker level. Partial response defined as either the disappearance of all target lesions and the persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits, or, at least a 30% decrease in the sum of the longest diamer (LD) of target lesions, taking as reference the baseline sum LD and no new lesions and/or unequivocal progression of existing non-target lesions.

Time frame:
After 9 weeks of treatment (at the end of Cycle 3)
Reported as:
Number · Percentage of participants
Percentage of Participants With an Overall Objective Response
Percentage of participantsPaclitaxel/Carboplatin + Motesanib 50 mg QDPaclitaxel/Carboplatin + Motesanib 125 mg QDPaclitaxel/Carboplatin + Motesanib 75 mg BIDPanitumumab + Motesanib 50 mg QDPanitumumab + Motesanib 125 mg QDPanitumumab + Motesanib 75 mg BIDPanitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QD
Percentage of Participants With an Overall Objective Response3318000017
PrimaryMaximum Observed Plasma Concentration of Motesanib (Cmax) in Cycle 1

The maximal observed plasma concentration of motesanib after a single dose dose in Cycle 1. For the 75 mg BID cohorts, Cmax is reported for the first daily dose.

Time frame:
Cycle 1, Day 3 at predose, 15 and 30 min, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration of Motesanib (Cmax) in Cycle 1
ng/mLPaclitaxel/Carboplatin + Motesanib 50 mg QDPaclitaxel/Carboplatin + Motesanib 125 mg QDPaclitaxel/Carboplatin + Motesanib 75 mg BIDPanitumumab + Motesanib 50 mg QDPanitumumab + Motesanib 125 mg QDPanitumumab + Motesanib 75 mg BIDPanitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QD
Maximum Observed Plasma Concentration of Motesanib (Cmax) in Cycle 1158 ± 55525 ± 250448 ± 112328 ± 214444 ± 130198 ± 55360 ± 243
PrimaryEstimated Terminal-phase Half-life (t1/2,z) of Motesanib in Cycle 1

The terminal-phase elimination half-life (t1/2,z) of motesanib was calculated as ln(2)/λz. The terminal elimination rate constant (λz) was determined by linear regression of the natural logarithms of at least the last 3 measurable concentrations during the terminal phase. For the 75 mg BID cohorts, t1/2,z is reported for the first daily dose.

Time frame:
Cycle 1, Day 3 at predose, 15 and 30 min, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours postdose.
Reported as:
Mean · hours
Estimated Terminal-phase Half-life (t1/2,z) of Motesanib in Cycle 1
hoursPaclitaxel/Carboplatin + Motesanib 50 mg QDPaclitaxel/Carboplatin + Motesanib 125 mg QDPaclitaxel/Carboplatin + Motesanib 75 mg BIDPanitumumab + Motesanib 50 mg QDPanitumumab + Motesanib 125 mg QDPanitumumab + Motesanib 75 mg BID
Estimated Terminal-phase Half-life (t1/2,z) of Motesanib in Cycle 17.34 ± 2.075.33 ± 1.055.77 ± 1.456.47 ± 2.317.57 ± 2.608.28 ± 2.62
PrimaryArea Under the Plasma Concentration-time Curve for Motesanib in Cycle 1

Area under the plasma concentration-time curve for motesanib in Cycle 1 calculated using the using the linear/log trapezoidal method. AUC from time zero to infinity (AUC0-inf) is reported for the 50 and 125 mg QD cohorts and AUC from time 0 to 24 hours post-dose (AUC0-24) is reported for the 75 mg BID cohort, where AUC0-24 is the sum of AUC0-12 for the first and second daily dose.

Time frame:
Cycle 1, Day 3 at predose, 15 and 30 minutes, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.
Reported as:
Mean · μg*hr/mL
Area Under the Plasma Concentration-time Curve for Motesanib in Cycle 1
μg*hr/mLPaclitaxel/Carboplatin + Motesanib 50 mg QDPaclitaxel/Carboplatin + Motesanib 125 mg QDPaclitaxel/Carboplatin + Motesanib 75 mg BIDPanitumumab + Motesanib 50 mg QDPanitumumab + Motesanib 125 mg QDPanitumumab + Motesanib 75 mg BID
Area Under the Plasma Concentration-time Curve for Motesanib in Cycle 10.971 ± 0.3003.21 ± 1.122.91 ± 1.011.74 ± 0.633.23 ± 1.832.04 ± 1.06
PrimaryTrough Plasma Concentration at 24 Hours Post-dose (C24) for Motesanib in Cycle 1

The trough plasma concentration for motesanib at 24 hours postdose in Cycle 1. For the 75 BID cohort, C24 is the observed concentration at 24 hours (ie, after the second daily dose).

Time frame:
Cycle 1, Day 3, 24 hours post-dose
Reported as:
Mean · ng/mL
Trough Plasma Concentration at 24 Hours Post-dose (C24) for Motesanib in Cycle 1
ng/mLPaclitaxel/Carboplatin + Motesanib 50 mg QDPaclitaxel/Carboplatin + Motesanib 125 mg QDPaclitaxel/Carboplatin + Motesanib 75 mg BIDPanitumumab + Motesanib 50 mg QDPanitumumab + Motesanib 125 mg QDPanitumumab + Motesanib 75 mg BID
Trough Plasma Concentration at 24 Hours Post-dose (C24) for Motesanib in Cycle 19.12 ± 4.1726.5 ± 16.856.7 ± 27.414.0 ± 11.732.5 ± 21.556.8 ± 21.1
PrimaryTime to Maximum Plasma Concentration of Motesanib (Tmax) in Cycle 2

The time after dosing that the maximal plasma concentration of motesanib was observed in Cycle 2. For the 75 mg BID cohorts, Tmax is reported for the first daily dose.

Time frame:
Cycle 2, Day 1 at predose, 15 and 30 min, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.
Reported as:
Median · hours
Time to Maximum Plasma Concentration of Motesanib (Tmax) in Cycle 2
hoursPaclitaxel/Carboplatin + Motesanib 50 mg QDPaclitaxel/Carboplatin + Motesanib 125 mg QDPaclitaxel/Carboplatin + Motesanib 75 mg BIDPanitumumab + Motesanib 50 mg QDPanitumumab + Motesanib 125 mg QDPanitumumab + Motesanib 75 mg BIDPanitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QD
Time to Maximum Plasma Concentration of Motesanib (Tmax) in Cycle 21.5 (1.0 to 2.0)1.0 (0.5 to 4.0)0.63 (0.25 to 4.0)1.0 (0.5 to 2.0)0.75 (0.25 to 2.0)1.0 (0.50 to 2.0)2.0 (0.5 to 2.0)
PrimaryMaximum Observed Plasma Concentration of Motesanib (Cmax) in Cycle 2

The maximal observed plasma concentration of motesanib in Cycle 2, after multiple doses. For the 75 mg BID cohorts, Cmax is reported for the first daily dose.

Time frame:
Cycle 2, Day 1 at predose, 15 and 30 min, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration of Motesanib (Cmax) in Cycle 2
ng/mLPaclitaxel/Carboplatin + Motesanib 50 mg QDPaclitaxel/Carboplatin + Motesanib 125 mg QDPaclitaxel/Carboplatin + Motesanib 75 mg BIDPanitumumab + Motesanib 50 mg QDPanitumumab + Motesanib 125 mg QDPanitumumab + Motesanib 75 mg BIDPanitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QD
Maximum Observed Plasma Concentration of Motesanib (Cmax) in Cycle 2148 ± 25748 ± 701390 ± 319265 ± 190672 ± 336242 ± 153651 ± 605
PrimaryEstimated Terminal-phase Half-life (t1/2,z) of Motesanib in Cycle 2

The terminal-phase elimination half-life (t1/2,z) of motesanib was calculated as ln(2)/λz. The terminal elimination rate constant (λz) was determined by linear regression of the natural logarithms of at least the last 3 measurable concentrations during the terminal phase. For the 75 mg BID cohorts, t1/2,z is reported for the first daily dose.

Time frame:
Cycle 2, Day 1 at predose, 15 and 30 min, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.
Reported as:
Mean · hours
Estimated Terminal-phase Half-life (t1/2,z) of Motesanib in Cycle 2
hoursPaclitaxel/Carboplatin + Motesanib 125 mg QDPaclitaxel/Carboplatin + Motesanib 75 mg BIDPanitumumab + Motesanib 50 mg QDPanitumumab + Motesanib 125 mg QD
Estimated Terminal-phase Half-life (t1/2,z) of Motesanib in Cycle 26.41 ± 2.086.36 ± 1.707.08 ± 0.354.90 ± 1.21
PrimaryArea Under the Plasma Concentration-time Curve From Time 0 to 24 Hours Post-dose for Motesanib in Cycle 2

Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC0-24) for motesanib in Cycle 2 calculated using the using the linear/log trapezoidal method. For the 75 mg BID cohort AUC0-24 is the sum of AUC0-12 for the first and second daily dose.

Time frame:
Cycle 2, Day 1 at predose, 15 and 30 minutes, and at 1, 2, 4, 6, 10 (QD cohorts only), and 24 hours post-dose.
Reported as:
Mean · μg*hr/mL
Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours Post-dose for Motesanib in Cycle 2
μg*hr/mLPaclitaxel/Carboplatin + Motesanib 125 mg QDPaclitaxel/Carboplatin + Motesanib 75 mg BIDPanitumumab + Motesanib 50 mg QDPanitumumab + Motesanib 125 mg QDPanitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QD
Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours Post-dose for Motesanib in Cycle 24.50 ± 2.623.11 ± 2.381.26 ± 0.613.92 ± 2.653.16 ± 1.20
PrimaryTrough Plasma Concentration at 24 Hours Post-dose (C24) for Motesanib in Cycle 2

The trough plasma concentration for motesanib at 24 hours postdose in Cycle 2. For the 75 BID cohort, C24 is the observed concentration at 24 hours (ie, after the second daily dose).

Time frame:
Cycle 2, Day 1, 24 hours post-dose
Reported as:
Mean · ng/mL
Trough Plasma Concentration at 24 Hours Post-dose (C24) for Motesanib in Cycle 2
ng/mLPaclitaxel/Carboplatin + Motesanib 125 mg QDPaclitaxel/Carboplatin + Motesanib 75 mg BIDPanitumumab + Motesanib 50 mg QDPanitumumab + Motesanib 125 mg QDPanitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QD
Trough Plasma Concentration at 24 Hours Post-dose (C24) for Motesanib in Cycle 243.4 ± 44.845.4 ± 35.910.4 ± 5.361.1 ± 72.645.1 ± 37.9

Adverse events

Collected over First dose through 30 days after last dose; maximum time on treatment was 322 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paclitaxel/Carboplatin + Motesanib 50 mg QD—5/6 (83.3%)6/6 (100%)
Paclitaxel/Carboplatin + Motesanib 125 mg QD—2/11 (18.2%)11/11 (100%)
Paclitaxel/Carboplatin + Motesanib 75 mg BID—3/6 (50%)6/6 (100%)
Panitumumab + Motesanib 50 mg QD—0/4 (0%)4/4 (100%)
Panitumumab + Motesanib 125 mg QD—1/7 (14.3%)7/7 (100%)
Panitumumab + Motesanib 75 mg BID—4/5 (80%)5/5 (100%)
Panitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QD—2/6 (33.3%)6/6 (100%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventPaclitaxel/Carboplatin + Motesanib 50 mg QDPaclitaxel/Carboplatin + Motesanib 125 mg QDPaclitaxel/Carboplatin + Motesanib 75 mg BIDPanitumumab + Motesanib 50 mg QDPanitumumab + Motesanib 125 mg QDPanitumumab + Motesanib 75 mg BIDPanitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QD
CholecystitisHepatobiliary disorders0/60/111/60/40/72/50/6
DyspnoeaRespiratory, thoracic and mediastinal disorders2/60/110/60/40/70/50/6
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/60/110/60/40/70/51/6
Abdominal painGastrointestinal disorders0/60/110/60/40/71/51/6
DiarrhoeaGastrointestinal disorders0/60/110/60/40/71/50/6
NauseaGastrointestinal disorders0/60/110/60/40/71/51/6
VomitingGastrointestinal disorders0/60/110/60/40/71/50/6
Staphylococcal sepsisInfections and infestations0/60/110/60/40/71/50/6
AnorexiaMetabolism and nutrition disorders0/60/110/60/40/71/50/6
Cognitive disorderNervous system disorders0/60/110/60/40/71/50/6
Most frequent other events
Showing 10 of 191
Most frequent other events
EventPaclitaxel/Carboplatin + Motesanib 50 mg QDPaclitaxel/Carboplatin + Motesanib 125 mg QDPaclitaxel/Carboplatin + Motesanib 75 mg BIDPanitumumab + Motesanib 50 mg QDPanitumumab + Motesanib 125 mg QDPanitumumab + Motesanib 75 mg BIDPanitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QD
DiarrhoeaGastrointestinal disorders3/67/116/60/45/73/55/6
FatigueGeneral disorders5/68/114/62/46/75/55/6
Dermatitis acneiformSkin and subcutaneous tissue disorders0/61/110/61/43/73/56/6
PruritusSkin and subcutaneous tissue disorders1/62/110/60/46/73/53/6
NauseaGastrointestinal disorders4/66/115/61/43/72/54/6
VomitingGastrointestinal disorders4/64/115/60/41/74/51/6
HypomagnesaemiaMetabolism and nutrition disorders1/65/115/62/43/74/52/6
Exfoliative rashSkin and subcutaneous tissue disorders0/61/111/63/43/70/50/6
StomatitisGastrointestinal disorders0/63/112/60/43/71/54/6
Pain in extremityMusculoskeletal and connective tissue disorders1/60/111/60/40/70/54/6

Baseline characteristics

The analysis is based on the Safety Analysis Set which consists of all consented participants who received at least one dose of motesanib.

Age, Continuous
Age, Continuous(years)Paclitaxel/Carboplatin + Motesanib 50 mg QDPaclitaxel/Carboplatin + Motesanib 125 mg QDPaclitaxel/Carboplatin + Motesanib 75 mg BIDPanitumumab + Motesanib 50 mg QDPanitumumab + Motesanib 125 mg QDPanitumumab + Motesanib 75 mg BIDPanitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QDTotal
Mean67.8 ± 7.855.7 ± 12.764.5 ± 6.157.5 ± 9.964.0 ± 9.651.6 ± 14.659.0 ± 5.559.9 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Paclitaxel/Carboplatin + Motesanib 50 mg QDPaclitaxel/Carboplatin + Motesanib 125 mg QDPaclitaxel/Carboplatin + Motesanib 75 mg BIDPanitumumab + Motesanib 50 mg QDPanitumumab + Motesanib 125 mg QDPanitumumab + Motesanib 75 mg BIDPanitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QDTotal
Female043051316
Male673424329
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Paclitaxel/Carboplatin + Motesanib 50 mg QDPaclitaxel/Carboplatin + Motesanib 125 mg QDPaclitaxel/Carboplatin + Motesanib 75 mg BIDPanitumumab + Motesanib 50 mg QDPanitumumab + Motesanib 125 mg QDPanitumumab + Motesanib 75 mg BIDPanitumumab + Paclitaxel/Carboplatin + Motesanib 125 mg QDTotal
White or Caucasian6115464541
Asian00001012
Black or African American00100102
09

Study locations

No study locations are listed for this record.

10

References and documents

Publications

  • Blumenschein GR Jr, Reckamp K, Stephenson GJ, O'Rourke T, Gladish G, McGreivy J, Sun YN, Ye Y, Parson M, Sandler A. Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res. 2010 Jan 1;16(1):279-90. doi: 10.1158/1078-0432.CCR-09-1675. Epub 2009 Dec 22. PubMed 20028752 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005, a primary completion of Mar 2007 and a completion of Mar 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 7 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2004
First posted
Oct 27, 2004
Start
Jan 2005
Primary completionActual
Mar 2007
CompletionActual
Mar 2007
Results first posted
Mar 24, 2014
Last update
Mar 24, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00094835
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 27, 2004
Start date
Jan 2005
Primary completion
Mar 2007
Completion
Mar 2007
Results posted
Mar 24, 2014
Last update
Mar 24, 2016

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Panitumumab

Start the discussion